RNA interference agents to inhibit the expression of activin receptor-like kinase 7 (alk7), their compositions and methods of use.

Abstract

RNA interference (RNAi) agents, compositions including RNAi agents, and methods for inhibiting the activin receptor-like kinase 7 (ALK7) gene are described. The ALK7 RNAi agents and their conjugates described here inhibit ALK7 gene expression. Pharmaceutical compositions including one or more ALK7 RNAi agents, optionally with one or more additional drugs, are also described. In vivo administration of the described ALK7 RNAi agents to adipose tissue results in the inhibition of ALK7 gene expression and a reduction in its activity, which may provide a therapeutic benefit to patients, including humans, for the treatment of various diseases such as obesity, diabetes, or insulin resistance.